Fluorescein Angiography

Global Fluorescein Angiography Market to Reach US$1.3 Billion by 2030

The global market for Fluorescein Angiography estimated at US$829.5 Million in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Traditional Fluorescein Angiography, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$922.8 Million by the end of the analysis period. Growth in the Confocal Scanning Laser Ophthalmoscopy segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$226.0 Million While China is Forecast to Grow at 12.2% CAGR

The Fluorescein Angiography market in the U.S. is estimated at US$226.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$277.8 Million by the year 2030 trailing a CAGR of 12.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Fluorescein Angiography Market – Key Trends & Drivers Summarized

Why Is Fluorescein Angiography Gaining Importance in Ophthalmology?

Fluorescein angiography (FA) is a vital diagnostic imaging technique used to assess blood flow in the retina and choroid, aiding in the early detection and management of eye disorders such as diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusions. The rising prevalence of diabetes and an aging global population are fueling demand for advanced retinal imaging solutions. Additionally, improvements in teleophthalmology and AI-powered image analysis are enhancing the accessibility and accuracy of FA procedures. As the burden of vision-related diseases grows, healthcare providers are increasingly relying on fluorescein angiography for accurate diagnosis and treatment planning.

What Technological Advancements Are Improving Fluorescein Angiography?

Advancements in high-speed digital imaging, AI-driven diagnostic tools, and ultra-widefield angiography are transforming FA technology. AI-powered image analysis software is improving early disease detection by automatically identifying abnormal vascular patterns and leakages. The development of non-invasive and contrast-free angiography techniques, such as optical coherence tomography angiography (OCTA), is reducing patient discomfort while maintaining diagnostic accuracy. Additionally, innovations in hyperspectral imaging are enabling more detailed visualization of retinal microcirculation. The integration of cloud-based ophthalmic imaging platforms is also improving collaboration between specialists, facilitating remote diagnosis and second-opinion consultations.

How Are Regulations and Market Trends Influencing Fluorescein Angiography?

Regulatory agencies such as the FDA, EMA, and WHO enforce strict guidelines for contrast agents used in FA procedures, ensuring patient safety and imaging quality. The shift toward non-invasive diagnostic methods is driving research into alternative angiography techniques with fewer side effects. Additionally, the expansion of AI-assisted ophthalmology is influencing market trends, allowing for faster and more precise diagnostic workflows. The rising demand for portable and home-based retinal imaging solutions is also encouraging the development of compact FA devices. As ophthalmic imaging technology evolves, fluorescein angiography is becoming more patient-friendly and diagnostically efficient.

What’s Driving the Future Growth of the Fluorescein Angiography Market?

The future of FA is being shaped by AI-powered predictive diagnostics, next-generation imaging contrast agents, and the integration of telemedicine in ophthalmology. The rise of personalized medicine and targeted therapies will drive demand for more precise retinal imaging techniques. The increasing use of AI-assisted decision-making tools will further improve diagnostic accuracy and workflow efficiency. Additionally, the development of non-invasive, label-free imaging technologies will reduce reliance on dye-based angiography, minimizing patient risks. As vision care continues to advance, FA will remain a cornerstone of ophthalmic diagnostics, supporting early disease detection and improved patient outcomes.

SCOPE OF STUDY:

The report analyzes the Fluorescein Angiography market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Traditional Fluorescein Angiography, Confocal Scanning Laser Ophthalmoscopy); Application (Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis & Retinal Vasculitis, Choroidal Tumors, Others); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Alcon Laboratories, Inc.
• Bayer AG
• Canon Inc.
• Carl Zeiss Meditec AG
• CenterVue SpA
• Chongqing Vision Star Optical Co., Ltd.
• Clarity Medical Systems, Inc.
• Eyenuk, Inc.
• Eye-Tech
• Forus Health Pvt Ltd.
• FOSHAN CONCERN MEDICAL EQUIPMENT CO.,LTD.
• Guangzhou Happycare Medical Equipment
• Heidelberg Engineering GmbH
• Imagine Eyes
• Johnson & Johnson Vision Care, Inc.
• Kowa Company Ltd.
• Marco Ophthalmic, Inc.
• NIDEK Co., Ltd.
• Novartis AG
• Optomed Oy (Ltd.)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.